Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;15(6):e70617.
doi: 10.1002/brb3.70617.

MCP-1 Is Elevated in the Cerebral Fluid of Children With Tourette Syndrome: Case Series and Literature Review

Ke Zhongling  1 , Chen Mengxin  1 , Huang Yuxian  1 , Chen Yanhui  1
Affiliations
Review

MCP-1 Is Elevated in the Cerebral Fluid of Children With Tourette Syndrome: Case Series and Literature Review

Ke Zhongling et al. Brain Behav. 2025 Jun.

Abstract

Purpose: This study aims to investigate cerebrospinal fluid (CSF) in patients with Tourette syndrome (TS) to identify the role of neuroinflammation in the pathophysiology of TS.

Methods: We retrospectively reported cerebrospinal fluid (CSF) examination in four male adolescents diagnosed with severe TS, as indicated by a high Yale Global Tic Severity Scale (YGTSS) score. The examination included routine and biochemical tests, oligoclonal band testing, and analysis of 14 neural autoantibodies. Furthermore, the levels of 34 cytokines were also measured.

Findings: CSF examinations revealed that routine and biochemical tests were normal and that no oligoclonal bands were detected. The 14 neural autoantibodies tested were negative. Among the 34 cytokines analyzed, only monocyte chemoattractant protein-1 (MCP-1) levels were significantly elevated.

Conclusions: This study is the first to report elevated levels of MCP-1 in the CSF of patients with TS. Our findings suggest that MCP-1-associated neuroinflammation may play a crucial role in the pathogenesis of TS, indicating that targeting MCP-1 could be a promising therapeutic approach to managing symptoms of TS.

Keywords: CSF; MCP‐1; Tourette syndrome; immunologic; neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Addabbo, F. , Baglioni V., Schrag A., et al. 2020. “Anti‐Dopamine D2 Receptor Antibodies in Chronic Tic Disorders.” Developmental Medicine and Child Neurology 62, no. 10: 1205–1212. 10.1111/dmcn.14613. - DOI - PubMed
    1. Augustine, F. , and Singer H. S.. 2019. “Merging the Pathophysiology and Pharmacotherapy of Tics.” Tremor Other Hyperkinet Mov (N Y) 8: 595. 10.7916/D8H14JTX. - DOI - PMC - PubMed
    1. Baumgaertel, C. , Skripuletz T., Kronenberg J., et al. 2019. “Immunity in Gilles de la Tourette‐Syndrome: Results From a Cerebrospinal Fluid Study.” Frontiers in Neurology 10, no. JUL: 732. 10.3389/fneur.2019.00732. - DOI - PMC - PubMed
    1. Cédile, O. , Wlodarczyk A., and Owens T.. 2017. “CCL2 recruits T Cells Into the Brain in a CCR2‐Independent Manner.” Apmis 125, no. 11: 945–956. 10.1111/apm.12740. - DOI - PubMed
    1. Cerri, C. , Genovesi S., Allegra M., et al. 2016. “The Chemokine CCL2 Mediates the Seizure‐Enhancing Effects of Systemic Inflammation.” Journal of Neuroscience 36, no. 13: 3777–3788. 10.1523/JNEUROSCI.0451-15.2016. - DOI - PMC - PubMed